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Abstract
Lower respiratory tract infections caused by influenza A continue to exact unacceptable worldwide mortality, and recent
epidemics have emphasized the importance of preventative and containment strategies. We have previously reported that
induction of the lungs’ intrinsic defenses by aerosolized treatments can protect mice against otherwise lethal challenges
with influenza A virus. More recently, we identified a combination of Toll like receptor (TLR) agonists that can be aerosolized
to protect mice against bacterial pneumonia. Here, we tested whether this combination of synthetic TLR agonists could
enhance the survival of mice infected with influenza A/HK/8/68 (H3N2) or A/California/04/2009 (H1N1) influenza A viruses.
We report that the TLR treatment enhanced survival whether given before or after the infectious challenge, and that
protection tended to correlate with reductions in viral titer 4 d after infection. Surprisingly, protection was not associated
with induction of interferon gene expression. Together, these studies suggest that synergistic TLR interactions can protect
against influenza virus infections by mechanisms that may provide the basis for novel therapeutics.
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Introduction
Worldwide, lower respiratory tract infections cause more
premature death and disability than any other condition [1,2,3].
Most years, seasonal influenza pneumonia alone causes more than
40,000 deaths in the United States, despite vaccination programs
that have been in place for decades [4,5]. Pandemic influenzas
have even more profound mortality impacts, with more than 50
million influenza-related deaths reported in 1918–9 [6]. The
ongoing susceptibility of populations to pandemic influenza was
emphasized by the rapid international spread of swine-origin
H1N1 influenza in 2009 [7,8,9]. Further, the anticipated human-
to-human transmission of avian-origin H5N1 influenza, which has
already claimed 335 lives worldwide (www.who.int/csr/disease/
avian_influenza/) by zoonotic transmission, serves as an obvious
indicator of the persisting risk of pandemics [9,10]. Respiratory
viruses, including influenza, have also been characterized as
potential agents of bioterror [11].
While a universal influenza vaccine is desirable, efficacy of such
a vaccine capable of protecting against future pandemics has not
yet been demonstrated [12]. Moreover, it is inevitable in the
foreseeable future that populations will remain susceptible to
seasonal influenza due to incomplete seasonal vaccination
programs [13,14,15,16], epidemiologically-predicted trivalent
vaccines that fail to confer immunity to a prevalent strain
[17,18], and host factors that impair initiation or maintenance
of vaccine-induced immunity [19,20,21].
These concerns led us to investigate whether the intrinsic
defense mechanisms of the lungs could be stimulated to broadly
protect against pneumonias, independent of vaccine status. We
have previously reported that stimulation of lung innate immunity
with an aerosolized bacterial lysate could protect against
pneumonia caused by bacterial, fungal and viral pathogens,
including otherwise lethal influenza A challenges [22,23,24,25,
26,27]. More recently, we reported that an aerosolized com-
bination of synthetic Toll-like receptor (TLR) agonists could
recapitulate the protection conferred by the lysate against bacterial
infections [25,28], leading to the question of whether protection
against viral pneumonia could also be achieved using this novel
combination of TLR ligands. Here, we report that synthetic
ligands for TLR2/6 and TLR9 induce robust protection against
lethal influenza pneumonia, including from swine-origin H1N1
influenza.
Results
Synergistic TLR2/6 and TLR9 stimulation protects against
lethal influenza pneumonia
Wildtype mice were challenged with a lethal inoculum of
influenza A/Hong Kong/8/68 (H3N2) 1 d after a single
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aerosolized treatment with synthetic TLR ligand(s) or PBS (sham),
then observed for 22 d. Treatment of mice with a TLR2/6 agonist
(Pam2CSK4, ‘‘Pam2’’) alone or a TLR9 agonist (ODN2395,
‘‘ODN’’) alone resulted in no protection against lethal influenza
pneumonia. However, when both treatments were concurrently
delivered (Pam2-ODN) prior to the viral challenge, survival of the
infectious challenge was significantly enhanced (Figure 1A).
Similarly, while the mean weight loss of mice treated with single
ligands did not differ from the infection-related weight loss of
sham-treated mice, the mean weight loss of mice treated with
Pam2-ODN was significantly less (p,0.05) than that of the sham-
treated mice for days 4–14 after infection (Figure 1B). The non-
significant weight differences observed after day 14 reflect the
recovery phase of just two surviving PBS-treated mice and the
heterogeneous recovery rates in the Pam2-ODN treated mice.
Intuitively, the weight curves of the surviving Pam2-ODN-treated
mice and the PBS-treated mice would be expected to eventually
converge at a time beyond the period of observation. As the
induced protective effect was substantially greater than additive
effect of the individual TLR ligands alone, the Pam2-ODN-
induced protection is recognized as synergistic in nature. This is
consistent with the synergistic protection we have previously
observed in mice pretreated with this TLR ligand combination
prior to bacterial challenges [28].
TLR-induced resistance to influenza pneumonia is
inducible before or after infection
Our previous studies of inducible resistance indicate that the
stimulating treatment can be delivered after the infectious
challenge, even when mice are challenged with otherwise lethal
inocula of influenza [24,27,28]. To determine whether the
protective phenomenon of TLR synergy-induced resistance to
influenza was restricted to only prophylactic treatment 1 d
before viral exposure, mice were challenged after treatment
with Pam2-ODN 3 d prior to infection or 1 d after infection,
and compared to mice treated 1 d prior to infection or treated
with PBS alone. As shown in Figure 2A, survival was
significantly enhanced for each Pam2-ODN treatment group
compared to PBS-treated mice. Similarly, weight loss was less
for all of the Pam2-ODN treated groups by day 10 after
infection and this persisted through the end of the observation
period (p,0.05, Figure 2B). While the mice treated with Pam2-
ODN on the day after viral infection transiently averaged 1–2 g
less than the PBS treated mice (days 2 to 7), all three Pam2-
ODN treated groups exceeded the mean of the PBS treated
mice for most of the observation period. Consistent with our
prior observations [27], the greatest induced protection was
associated with the greatest reductions in the lung viral titers
4 d after infection (Figure 2C). However, as we have also
previously described, the nonsignificant trend towards reduc-
tion in viral titer in the mice treated with Pam2-ODN 3 d prior
to challenge suggests that early reductions in viral titer are
likely only one determinant of the inducible protection. The
authors postulate, for example, that treatment may also
attenuate the native, injurious inflammatory host response to
the virus, may enhance containment of the infection within the
lungs, may prevent death due to secondary bacterial infections
and may foster effective ongoing viral clearance in addition to
rapid induction of pathogen killing. And, much like the
cytokine-induced antiviral state is observed in certain leuko-
cytes, it is possible that the TLR stimulus may directly reduce
the ability of virus to infect its primary target, the respiratory
epithelium.
TLR3 stimulation does not enhance TLR2/6 and TLR9
protection against influenza pneumonia
Treatments that activate TLR3 in mice have been reported to
enhance antiviral immunity, including induction of protection
against influenza [29,30,31,32,33]. We tested whether treatment
of mice with the TLR3 agonist poly(I:C) would protect against
influenza in our lethal infection model. As shown in Figure 3A, we
found that poly(I:C) treatment delivered 1 d prior to influenza
challenge did result in improved survival, supporting the prior
literature. However, a single treatment with poly(I:C) resulted in
less protection than a single treatment with Pam2-ODN.
Moreover, the addition of poly(I:C) had no discernable effect on
the synergistic response to Pam2-ODN, as the concurrent
Figure 1. Synergistic TLR stimulation protects against lethal
influenza pneumonia, while individual TLR ligands confer no
protection. Swiss-Webster mice were challenged with influenza A/
Hong Kong/8/68 (H3N2) 24 h after aerosolized treatment with PBS
(sham), Pam2, ODN or both (Pam2-ODN). Shown are survival (A) and
body weight (B) of the mice through day 22 after infection (mean 6
s.d.). (n = 20 mice/group; *p = 0.03 vs. PBS treated).
doi:10.1371/journal.pone.0030596.g001
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administration of the TLR3 ligand with the TLR2/6 and TLR9
ligands resulted in no significant differences in survival or body
weight. We found that doubling the concentration of Pam2-ODN
further improved survival to 100% (Figure 3). At this level of
protection, the survival and weight changes of the 1x and 2x
Pam2-ODN-treated groups cannot be statistically distinguished
from each other. However, it is notable that the increased dose was
Figure 2. Synergistic TLR stimulation protects against influen-
za pneumonia whether given before or after infection. Mice
were challenged with influenza A following a single aerosolized
treatment with Pam2-ODN 3 d before infection, 1 d before infection
or 1 d after infection or following a single aerosol treatment with PBS
1 d before infection. Shown are survival (A) and body weight (B) of the
mice through day 22 after infection (mean 6 s.d.). Log viral titer of lung
homogenates is shown for day 4 after infection for the same groups (C,
Figure 3. Synergistic TLR2/6 and TLR9 protects against
influenza with or without TLR3 stimulation. Mice were challenged
with influenza 1 day after a single inhaled treatment with the described
treatments. Shown are survival (A) and body weight (B) of mice
through 22 days after challenge (mean 6 s.d.). ‘‘2x’’ indicates doubling
of the concentration of all TLR ligand components in a corresponding
‘‘1x’’ treatment. (n = 20 mice/group; * p,0.00001 vs. PBS treated, **
p,0.02 vs. PBS treated, { p,0.0001 vs. poly(I:C) treated, {{ p= 0.002 vs.
poly(I:C) treated, # p=0.004 vs. poly(I:C) treated).
doi:10.1371/journal.pone.0030596.g003
mean 6 s.d.). (n = 20 mice group for survival and weight, n – 5 mice/
group for lung titers; * p,0.0001 vs. PBS treated, ** p,0.002 vs. PBS
treated, { p,0.05 vs. PBS treated).
doi:10.1371/journal.pone.0030596.g002
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well tolerated by the mice, inducing neither distress nor worsening
survival.
Protection is not associated with induction of lung
interferon expression
Our prior studies of lysate-induced resistance to influenza
revealed significant induction of both type I and type II interferon
expression [27]. Given prior data suggesting that lung epithelial
cells play a critical role in inducible resistance [22,24,26,28], we
first assessed Pam2-ODN-induced interferon signaling in MLE-15
lung epithelial cells in isolation. As shown in Table 1, we did not
observe the induction of type I, II or III interferon expression by
these cells following treatment with Pam2-ODN, despite analyzing
identical time points to those studied when investigating lysate-
induced protection. While the epithelium appears to play an
important role in inducible resistance, we recognized that
recruited leukocytes might be the source of the previously observed
lysate-induced interferons in the lungs. So, wildtype mice were
treated with Pam2-ODN or PBS, and interferon gene expression
was analyzed in whole lung homogenates. Again, we did not detect
significant induction of interferon genes or known interferon-
sensitive antiviral genes by Pam2-ODN treatment, although we
did find induction of some interferon receptors. Although there
was significant induction of Janus Kinase 1 (JAK1, p,0.01), JAK2
(p,0.00001), and Signal Transducer and Activator of Transcrip-
tion 1 (STAT1, p,0.00001) expression following PAM2-ODN
treatment, pathway analysis did not associate inducible resistance
with TLR-enriched interferon signaling (compared to PBS-
treated, p = 1.0). To ensure that the absence of interferon-related
gene expression was not the result of an insufficient therapeutic
stimulus or an insensitive detection technique, we also analyzed
interferon-independent, pro-inflammatory cytokine gene expres-
sion. Table 2 presents 15 representative examples of these pro-
inflammatory cytokines and chemokines that are significantly
enriched in the same samples analyzed in Table 1. Unlike the
negligible changes seen in the interferon-dependent genes,
treatment with Pam2-ODN results in robust expression of IL-6,
TNF, IL-1a, IL-1b, and multiple chemokines. In most examples,
these findings were observed from both MLE-15 cells in isolation
and from whole lung homogenates 4 h after Pam2-ODN
treatment.
The role of these inflammatory cytokines in inducible resistance
remains unclear. IL-6 and TNF were even more robustly induced
by the lysate than by Pam2-ODN, but we have shown that they
were not required for protection against bacterial pneumonia [24].
Also, given the demonstrations of tachyphylaxis to leukocyte
infiltration, but not protection, with repetitive treatments, the
induction of these products may represent an epiphenomenon that
provides a useful biomarker but may be mechanistically
unimportant. However, it is interesting that the four pro-
inflammatory cytokines induced by Pam2-ODN 4 h after
treatment (IL-1a, IL-1b, IL-6, and TNF) are also the first four
pro-inflammatory cytokines induced from respiratory epithelial
cells in native influenza infections [34]. While the principal
antiviral function of these cytokines is generally presumed to be
leukocyte activation, it is conceivable that they also directly shape
the epithelial response and that they may eventually prove to be
required.
Class C CpG ODNs synergize most effectively with TLR2/6
agonist to protect against influenza pneumonia
We have reported that only class C CpG ODNs can effectively
activate TLR9 in a manner that synergizes with TLR2/6 to
protect against bacterial pneumonia [28]. To test whether class C
CpG ODNs are specifically required for TLR-inducible resistance
to influenza, we treated groups of mice with one of several
aerosolized treatments one day prior to influenza infection. The
treatments consisted of Pam2 plus one CpG ODN (class A, B or C)
or PBS only, as shown in Figure 4. In contrast to our experience
with the bacterial models, all classes of CpG ODNs synergized
with Pam2 to protect against influenza pneumonia. As a group,
the class C CpG ODNs again protected significantly better non-
Class C CpG ODNs (p = 0.025). However, all tested CpG ODNs
synergized to some extent with Pam2, and some Class A and Class
B CpG ODNs protected as well as Class C ligands when combined
with Pam2.
Synergistic TLR2/6 and TLR9 stimulation protects against
swine-origin H1N1 influenza
To confirm that Pam2-ODN-induced protection was not
restricted to a single influenza strain, we tested the ability of
Pam2-ODN to protect against highly lethal swine-origin H1N1
influenza. As shown in Figure 5, a single inhaled treatment with
Pam2-ODN significantly improved mouse survival of otherwise
lethal challenge.
Discussion
Viral lower respiratory tract infections, particularly those caused
by influenza viruses, continue to inflict tremendous annual
worldwide mortality [35]. Further compounding this public health
urgency are the persisting threat of pandemic influenza infection
and an increasing resistance to available antivirals, such as
neuraminidase inhibitors [36,37].
In this study, we find that induction of innate immunity in the
lungs with a novel combination of synthetic TLR ligands results in
robust protection against otherwise lethal influenza. Consistent
with our earlier descriptions of inducible resistance to influenza
pneumonia, this protection is generally associated with reductions
in the lung viral titers of treated mice [27], though this association
is not always observed. Also consistent with our reports of
protection induced by treatment of mice with an aerosolized
treatment with a bacterial lysate, protection could be induced
whether the treatment was applied before or after infection [27].
Type I and II interferon responses have both been identified by
other groups as essential to effective antiviral host responses
[38,39]. However, in notable contrast with our observations in
lysate-induced resistance to influenza pneumonia [27], we do not
find that Pam2-ODN treatment induces significant interferon-
related gene expression. As the current studies were not performed
in interferon-deficient mice, it is impossible to exclude any role for
low-level interferon signaling in Pam2-ODN-induced pneumonia.
However, these findings do suggest that reconsideration of the
lysate-induced changes in gene expression might be necessary. We
previously observed that the lysate induced significant type I and II
interferon signaling in the absence of infection, but we also
demonstrated that interferon -c levels in the lungs of infected mice
were lower if they had been pretreated with the aerosolized lysate.
At that time, we interpreted this to mean that the interferon
response was important to inducible resistance, but that the
effective interferon response also limited ongoing interferon
signaling following clearance of the pathogen. While that
interpretation may be correct, the new observation of protection
without induction of interferon signaling raises the competing
interpretation that interferon signaling is not required for either
lysate- or Pam2-ODN-induced resistance to pneumonia. This
would be consistent with other prior observations that interleukin-
TLR Synergy Protects against Influenza Pneumonia
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Table 1. Interferon responses to Pam2-ODN.
Symbol
MLE-15 Fold
Change
Lung Fold
Change Definition Accession
Bak1 « « Bcl2-antagonist/killer 1 NM_007523.2
Bax « Q 1.6 Bcl2-associated X protein NM_007527.2
Bcl2 « « B-cell leukemia/lymphoma 2, variant 2 NM_177410.2
Gvin1 « « GTPase, very large interferon inducible 1, variant B NM_001039160.2
Ifi202b « « Interferon activated gene 202B NM_008327.1
Ifi203 « « Interferon activated gene 203, transcript variant 2 NM_008328.2
Ifi204 « « Interferon activated gene 204 NM_008329.2
Ifi205 « « Interferon activated gene 205 NM_172648.3
Ifi27 « « Interferon alpha-inducible protein 27 NM_029803.1
Ifi30 « « Interferon gamma inducible protein 30 NM_023065.3
Ifi35 « Q 1.4 Interferon-induced protein 35 NM_027320.4
Ifi44 « « Interferon-induced protein 44 NM_133871.1
Ifi47 q 3.3 q 2.6 Interferon gamma inducible protein 47 NM_008330.1
Ifih1 « « Interferon induced with helicase C domain 1 NM_027835.1
Ifit1 « « Interferon-induced protein with tetratricopeptide repeats 1 NM_008331
Ifit2 « q 1.9 Interferon-induced protein with tetratricopeptide repeats 2 NM_008332.2
Ifit3 « « Interferon-induced protein with tetratricopeptide repeats 3 NM_010501.2
Ifitm1 « « Interferon induced transmembrane protein 1 NM_026820.2
Ifitm2 « q 1.6 Interferon induced transmembrane protein 2 NM_030694.1
Ifitm3 « « Interferon induced transmembrane protein 3 NM_025378.2
Ifitm5 « « Interferon induced transmembrane protein 5 NM_053088.2
Ifitm6 « « Interferon induced transmembrane protein 6 NM_001033632.1
Ifitm7 « « Interferon induced transmembrane protein 7 NM_028968.1
Ifna1 « « Interferon alpha 1 NM_010502.2
Ifna2 « « Interferon alpha 2 NM_010503.2
Ifna4 « « Interferon alpha 4 NM_010504.1
Ifna5 « « Interferon alpha 5 NM_010505.1
Ifna6 « « Interferon alpha 6 NM_206871.1
Ifna7 « « Interferon alpha 7 NM_008334.2
Ifna9 « « Interferon alpha 9 NM_010507.1
Ifna11 « « Interferon alpha 11 NM_008333.1
Ifna12 « « Interferon alpha 12 NM_177361.2
Ifna13 « « Interferon alpha 13 NM_177347.2
Ifna14 « « Interferon, alpha 14 NM_206975.1
Ifnab « « Interferon alpha B NM_008336.2
Ifnar1 « « Interferon alpha and beta receptor 1 NM_010508.1
Ifnar2 « q 3.0 Interferon alpha and beta receptor 2 NM_010509.1
Ifnb1 « « Interferon beta 1, fibroblast NM_010510.1
Ifne1 « « Interferon epsilon 1 NM_177348.2
Ifng « « Interferon gamma NM_008337.1
Ifngr1 « q 1.4 Interferon gamma receptor 1 NM_010511.2
Ifngr2 q 2.5 q 1.7 Interferon gamma receptor 2 NM_008338.2
Ifnk « « Interferon kappa NM_199157.2
Ifnz « « Interferon zeta NM_197889.1
Ifrg15 « « Interferon alpha responsive gene 15 NM_022329.3
Igtp « q 1.4 Interferon gamma induced GTPase NM_018738.3
Iigp1 « « Interferon inducible GTPase 1 NM_021792.3
Iigp2 « q 1.5 Interferon inducible GTPase 2 NM_019440.2
Isg20 « « Interferon-stimulated protein 20 NM_020583.4
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6 and TNF are both profoundly induced by lysate treatment, but
are not required for protection against bacterial pneumonias [24].
While these data provide a novel contrast to prior reports of
interferon-dependence of the antiviral response, they do not
clearly reveal the interferon-independent mechanisms underlying
the protection. This is an area of active research, but we have
previously reported that Pam2-ODN is capable of inducing
expression of both antimicrobial peptides and reactive oxygen
species [22,23,24,25,26,27,28], and anticipate that these responses
contribute to both inducible viral killing and modulation of
untoward elements of the inflammatory response. We have also
shown in bacterial infection models that inducible resistance is
associated with enhanced containment of pathogens within the
lungs [22,24,28]. Enhancement of barrier function may contribute
to the antiviral response, as well. That this could occur in an
interferon-independent manner is supported by recent observa-
tions of reactive oxygen species mediated intercellular epithelial
antimicrobial communication [40].
Another unexpected finding was the observation that all tested
classed of TLR9-stimulating CpG ODNs were capable to some
degree of synergizing with Pam2 [28]. Synthetic CpG ODNs can
be structurally and functionally categorized into broad classes
[41,42,43,44]. Class A ODNs have palindromic sequences on
phosphodiester backbones and classically induce secretion of type I
and II interferons from leukocytes. Class B ODNs have linear 6-
mers on phosphorothioate backbones that induce B cell prolifer-
ation and expression of interleukins-6 and -10. Class C ODNs
possess characteristics of both A and B classes [43,45]. These class-
specific responses presumably arise from differential endosomal
compartmentalization and signaling, with Class A ODNs
predominantly promoting IRF-7-mediated signaling from early
endosomes and Class B ODNs primarily inducing late endosomal
NF-kB activation [43].
We have previously reported that only class C CpG ODNs
effectively synergized with the TLR2/6 ligands to protect broadly
against bacterial challenges. However, we here clearly demon-
strate that class A and class B CpG ODNs can cooperate with
Pam2 to protect against influenza viruses, with no discernable
statistical difference in the performance of Class A and Class B
ligands. This mechanistic difference between the bacterial and
Table 2. Inflammatory cytokine responses to Pam2-ODN.
Symbol MLE-15 Fold Change Lung Fold Change Definition Accession
Ccl2 « q 33.0 Chemokine (C-C motif) ligand 2 NM_011333.3
Ccl3 « q 53.5 Chemokine (C-C motif) ligand 3 NM_011337.2
Ccl7 « q 15.3 Chemokine (C-C motif) ligand 7 NM_013654.2
Cx3cl1 q 4.0 q 2.4 Chemokine (C-X3-C motif) ligand 1 NM_009142.3
Cxcl1 q 77.3 q 16.6 Chemokine (C-X-C motif) ligand 1 NM_008176.1
Cxcl2 q 7.9 q 14.4 Chemokine (C-X-C motif) ligand 2 NM_009140.2
Cxcl10 q 1.7 q 22.8 Chemokine (C-X-C motif) ligand 10 NM_021274.1
Cxcl13 « q 11.3 Chemokine (C-X-C motif) ligand 13 NM_018866.1
Cxcl15 q 5.0 « Chemokine (C-X-C motif) ligand 15 NM_011339.2
Cxcl16 q 2.4 q 1.3 Chemokine (C-X-C motif) ligand 16 NM_023158.6
Il1a « q 8.1 Interleukin 1 alpha NM_010554
Il1b « q 25.1 Interleukin 1 beta NM_008361
Il24 q 3.0 « Interleukin 24 NM_053095.1
Il6 « q 2.6 Interleukin 6 NM_031168.1
Tnf q 2.0 q 24.8 Tumor necrosis factor NM_013693.1
Transcriptional responses of interferon-independent inflammatory cytokines and chemokines 4 h after treatment of MLE-15 cells in vitro or mouse lungs in vivo with
Pam2-ODN.
Fold change compares Pam2-ODN-treated samples to PBS-treated samples.« indicates no significant change in gene expression between PBS treated and Pam2-ODN
treated samples, q indicates induction of transcription by Pam2-ODN, Q indicates repression of transcription by Pam2-ODN.
doi:10.1371/journal.pone.0030596.t002
Symbol
MLE-15 Fold
Change
Lung Fold
Change Definition Accession
Mx1 « « Myxovirus (influenza virus) resistance 1 NM_010846.1
Oas1a « « 29-59 oligoadenylate synthetase 1A NM_145211.1
Psmb8 « « Proteasome subunit beta type 8 NM_010724.1
Tap1 « « Transporter 1, ATP-binding cassette, sub-family B NM_013683.1
Transcriptional responses of interferon and known interferon-sensitive antiviral genes 4 h after treatment of MLE-15 cells in vitro or mouse lungs in vivo with Pam2-ODN.
Fold change compares Pam2-ODN-treated samples to PBS-treated samples.« indicates no significant change in gene expression between PBS treated and Pam2-ODN
treated samples, q indicates induction of transcription by Pam2-ODN, Q indicates repression of transcription by Pam2-ODN.
doi:10.1371/journal.pone.0030596.t001
Table 1. Cont.
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viral models will be an area of future investigation. However, as
class A and class C, but not class B, CpG ODNs are reported to
induce immune responses via interferon signaling, the observation
of Pam2 synergy with class B CpG ODNs is consistent with the
lack of an essential interferon role.
Because of these differences in Pam2-ODN-induced influenza
protection when compared to lysate-induced influenza protection
and to Pam2-ODN-induced bacterial protection, it was important
to show that this was not a phenomenon that was restricted to a
unique viral strain. We excluded that possibility by testing an
alternate influenza strain, and demonstrated the effectiveness of
this treatment against clinically-relevant pathogens by showing
that Pam2-ODN can also protect against swine-origin H1N1
influenza viruses.
This broad, non-toxic host response-focused strategy to
preventing influenza-related mortality may provide an opportunity
to protect vulnerable populations when vaccines are unavailable or
impractical, to contain outbreaks by treating contacts of incident
cases, and, potentially, to protect populations that have deficien-
cies of adaptive immunity.
Methods
Animals
Six to eight week old NIH Swiss-Webster mice (Charles River)
were used for all experiments. For protection studies, mice were
divided into groups of 20 mice (5 for virus lung titers, 15 for
Figure 4. Pam2 treatment synergizes with all classes of TLR9-
stimulating CpG oligodeoxynucleotides. Mice were challenged
with influenza 1 day after a single inhaled treatment with the described
treatments. Shown are survival (A) and body weight (B) of mice
through 22 days after challenge (mean 6 s.d.). (n = 20 mice/group; *
p,0.00001 vs. PBS treated, ** p = 0.0004 vs. PBS treated, { p= 0.01 vs.
Pam2+ODN 2006 treated, { p= 0.1 vs Pam2+ODN 2006 treated).
doi:10.1371/journal.pone.0030596.g004
Figure 5. Synergistic TLR stimulation protects against swine-
origin H1N1 influenza A pneumonia. Mice were challenged with
influenza 1 day after a single inhaled treatment with Pam2 and ODN.
Shown are survival (A) and body weight (B) of mice through 22 days
after challenge (mean 6 s.d.). (n = 20 mice/group; * p = 0.0004 vs. PBS
treated).
doi:10.1371/journal.pone.0030596.g005
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survival). All mice were handled in accordance with the policies of
the Baylor College of Medicine Institutional Animal Care and Use
Committee, full details of the study were approved by that body
(approval AN-2307), and any mice that exhibited signs of distress
were humanely euthanized.
Synthetic TLR Ligand aerosol treatment
All treatments were delivered by aerosol. All synthetic TLR
ligands were purchased from InvivoGen (San Diego, California),
reconstituted in endotoxin-free water, and suspended in 8 ml
sterile PBS at indicated concentrations. As we have previously
described [22,23,27,28], treatments were aerosolized to the
animals for 30 min from an AeroMist CA-209 nebulizer (CIS-
US) driven by 10 l/min air supplemented. The nebulizer was
connected by polyethylene tubing (30 cm622 mm) to a 10 liter
polyethylene exposure chamber, with an identical efflux tube
with a low resistance microbial filter (BB50T, Pall, East Hills,
NY) at its end vented to a biosafety hood. Dosing of the TLR
ligands was determined by the lowest nebulized concentration
required to induce leukocyte infiltration of the lungs, as we have
previously reported [28]. Accordingly, the following concentra-
tions were used in the nebulizer reservoir: Pam2 10 mg/ml;
poly(I:C) 100 mg/ml; ODN2395 20 mg/ml. Based on previous
experiments, [23,46] ligand concentrations in the airway lining
fluid are calculated to be Pam2 10 ng/ml; poly(I:C) 100 ng/ml;
ODN2395 20 ng/ml. Experiments explicitly using 2X dosing of
ligands used double these concentrations. Class comparisons of
different CpG ODNs used equimolar concentration of their
respective ODN as found in ODN2395 20 mg/ml. Sequences of
the tested ODNS were: Class A, ODN 1585 59-ggggtcaacgtt-
gagggggg-39 and ODN 2216 59-gggggacgatcgtcgggggg-39; Class
B, ODN 1826 59-tccatgacgttcctgacgtt-39 and ODN 2006 59-
tcgtcgttttgtcgttttgtcgtt-39; and, Class C, ODN 2395 59-tcgtcg-
ttttcggcgcgcgccg-39, ODN M362 59-tcgtcgtcgttcgaacgacgttgat-39
and ODN 1010159-tcgtcgttttcgcgcgcgccg-39.
Influenza A challenge
A clinical isolate of influenza A/Hong Kong/8/68 (H3N2) (A/
HK; Mouse Lung Pool 11-29-05) virus that had been passaged at
least nine times through mice was stored as frozen stock (2.86107
TCID50/ml) in the supernatant of mouse lung homogenates [47].
Stock was diluted 1:300–1:1,000 in 0.05% gelatin in Eagle’s
minimal essential medium (Sigma-Aldrich) and aerosolized for
20 min to achieve LD90 – LD100 (target 100 TDIC50/mouse).
Viral concentration in the nebulizer before and after aerosoliza-
tion and in lung homogenates was determined by hemagglutina-
tion assay of infected MDCK cells [48]. On day +4, 5 mice from
each group were sacrificed and their lungs removed. Lungs were
homogenized by beadbeating and the levels of virus determined.
Remaining mice in each group were observed daily for up to 21
days for overt illness, morbidity and mortality. Mice were weighed
on days 0 and +4, and three times weekly from day +7 until day
+21. Influenza A/California/04/2009 (H1N1) was obtained from
the Centers for Disease Control and Prevention (Atlanta, GA) as
MDCK passage 3 (CDC ID Number 200971204). The virus was
grown in MDCK cells [45] and on passage 10, a sucrose purified
tissue culture pool was prepared. The 30/50% sucrose interface
was collected (passage 11), aliquoted and used for aerosol infection
of mice. The titer of the stock virus was 9.8 TCID50/mL and was
diluted 1:400 in 0.05% gelatin-MEM before nebulization. The
diluted virus was added to the reservoir (9 mL) of an Aerotech II
neublizer (CIS-USA, Bedford, MA) flowing at 10 L of air/min
and used to treat mice as described above. The targeted dose after
20 min was estimated to be ,26104 TCID50/mouse.
Gene expression analysis
To better understand the host response to Pam2-ODN, gene
expression microarray analysis was performed after treatment with
Pam2, ODN, Pam2-ODN or PBS. For in vitro analyses,
immortalized mouse distal respiratory epithelial MLE-15 cells
[49] were provided by Dr. Jeffrey A. Whitsett, Cincinnati
Children’s Hospital Medical Center, and grown in monolayer to
approximately 80% confluence, then the designated treatments
were added to the culture media for 4 h, then the cells were
collected by scraping, as previously described [28]. For in vivo
analyses, wild type mice were exposed by aerosol to the designated
treatments, as described above, then euthanized after 4 h for
comparison to PBS-treated mice. The lungs were sterilely-resected
and mechanically homogenized. Total RNA was isolated from
lung homogenates and cell culture samples using the RNeasy
system (Qiagen), and cRNA was synthesized and amplified from
equal masses of total RNA using the Ilumina TotalPrep RNA
amplification kit (Ambion). Amplified cRNA was hybridized and
labeled on MouseRef-8 v2.0 Expression BeadChips (Illumina),
then scanned on an Illumina iScan. Primary microarray data were
deposited at the NCBI Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) consistent with MIAME standards (GEO
Accession GSE26864, in vitro, and GSE28994, in vivo). Primary
signal intensity was normalized between and within samples, and
differentially expressed genes were identified based on signal
change and inter-sample variation. Gene ontology analysis was
performed using the NIAID Database for Annotation, Visualiza-
tion and Integrated Discovery (DAVID) and the KEGG Database
(GenomeNet). Differentially expressed genes were mapped to
signaling pathways using Ingenuity Pathways Analysis 9.0
(Ingenuity Systems), and the pathway nodules were individually
reviewed.
To characterize the interferon-related gene expression changes
induced by Pam2-ODN, Table 1 presents a list of genes
containing all transcripts from the Ingenuity Pathway Analysis
canonical interferon signaling pathway, detected interferon-related
JAK-STAT-dependent transcripts in KEGG, and additional
interferon-sensitive antiviral transcripts identified by the authors.
Baseline signal intensity values of 1 were assigned to undetected
control transcripts in order to avoid reporting infinite fold change
values. Samples treated with single TLR ligands (Pam2 only or
ODN only) were analyzed but not presented, as they were not
deemed to yield additional information beyond that presented in
Table 1. Data from all tested conditions is included in the GEO
deposits referenced above.
Statistical methods
Summary statistics for virus in lung tissue were compared using
Student’s t-test. Proportions of mice surviving pathogen challenges
were compared using Fisher’s exact text on the final day of
observation, and log-rank comparisons of survival distribution
were performed using Kaplan-Meier estimation. Weight compar-
isons were made between experimental groups using two-tailed
Student’s t-test for each experimental day. All data shown are
representative of at least two independent experiments, and were
not combined for analysis because of modest differences in virus
challenge doses. Analyses were performed using SAS/STAT (SAS
Institute).
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